3'-(4-morpholinyl)-3'-deaminodaunorubicin is a synthetic derivative of daunorubicin that has been investigated as a potential anticancer agent. It exhibits increased activity compared to daunorubicin against certain cancer cell lines, particularly those resistant to daunorubicin. This enhanced activity is attributed to its improved ability to bind to DNA and inhibit DNA synthesis. The compound is synthesized through a multi-step process that involves modification of the daunorubicin molecule. Its effects on cancer cells are primarily mediated through its interaction with DNA, leading to cell cycle arrest and apoptosis. Research into this compound is motivated by the need to develop new and more effective anticancer therapies. The increased activity of 3'-(4-morpholinyl)-3'-deaminodaunorubicin against daunorubicin-resistant cells suggests its potential to overcome drug resistance in cancer treatment.'
3'-(4-morpholinyl)-3'-deaminodaunorubicin: RN given refers to parent cpd(8S-cis)-isomer; structure given in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
| ID Source | ID |
|---|---|
| PubMed CID | 93463 |
| MeSH ID | M0107145 |
| Synonym |
|---|
| 5,12-naphthacenedione, 8-acetyl-7,8,9,10-tetrahydro-6,8,11-trihydroxy-1-methoxy-10-((2,3,6-trideoxy-3-(4-morpholinyl)-alpha-l-lyxo-hexopyranosyl)oxy)-, (8s-cis)- |
| 5,12-naphthacenedione, 7,8,9,10-tetrahydro-8-acetyl-1-methoxy-10-((2,3,6-trideoxy-3-(4-morpholinyl)-alpha-l-lyxo-hexopyranosyl)oxy)-6,8,11-trihydroxy-, (8s-cis)- |
| brn 5232668 |
| 3'-(4-morpholinyl)-3'-deaminodaunorubicin |
| 94730-46-8 |
| 9-acetyl-6,9,11-trihydroxy-7-[(2r,4s,5r)-5-hydroxy-6-methyl-4-morpholin-4-yloxan-2-yl]oxy-4-methoxy-8,10-dihydro-7h-tetracene-5,12-dione |
| ccris 5081 |
| 79867-78-0 |
| morpholinodaunomycin |
| DTXSID40915341 |
| 3-acetyl-3,5,12-trihydroxy-10-methoxy-6,11-dioxo-1,2,3,4,6,11-hexahydrotetracen-1-yl 2,3,6-trideoxy-3-morpholin-4-ylhexopyranoside |
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 7 (100.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (12.37) All Compounds (24.57) |
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 7 (100.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||